Which has stronger earnings and valuation, SVRA or IVVD?

Invivyd has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Savara N/A N/A -$118.84M -$0.56 N/A Invivyd $53.43M 4.93 -$52.49M -$0.31 N/A

Is SVRA or IVVD more profitable?

Savara has a net margin of 0.00% compared to Invivyd's net margin of -138.90%. Invivyd's return on equity of -53.48% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -87.19% -66.42% Invivyd -138.90% -53.48% -41.56%

Which has higher valuation & earnings, IVVD or MGTX?

Invivyd has higher earnings, but lower revenue than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Invivyd $53.43M 4.93 -$52.49M -$0.31 N/A MeiraGTx $81.39M 15.84 -$114.20M -$1.48 N/A

Is IVVD or MGTX more profitable?

Invivyd has a net margin of -138.90% compared to MeiraGTx's net margin of -151.12%. MeiraGTx's return on equity of 0.00% beat Invivyd's return on equity. Company Net Margins Return on Equity Return on Assets Invivyd -138.90% -53.48% -41.56% MeiraGTx -151.12% N/A -54.96%

Does the media refer more to IVVD or MGTX?

In the previous week, Invivyd had 1 more articles in the media than MeiraGTx. MarketBeat recorded 2 mentions for Invivyd and 1 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.42 beat Invivyd's score of 0.00 indicating that MeiraGTx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invivyd 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MeiraGTx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer IVVD or CVAC?

Invivyd presently has a consensus target price of $8.00, suggesting a potential upside of 795.05%. Given Invivyd's stronger consensus rating and higher probable upside, research analysts clearly believe Invivyd is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invivyd 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, IVVD or CVAC?

CureVac has higher revenue and earnings than Invivyd. Invivyd is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Invivyd $53.43M 4.93 -$52.49M -$0.31 N/A CureVac $70.74M 14.78 $175.50M $0.72 6.47

Is IVVD or CVAC more profitable?

CureVac has a net margin of 199.92% compared to Invivyd's net margin of -138.90%. CureVac's return on equity of -23.03% beat Invivyd's return on equity. Company Net Margins Return on Equity Return on Assets Invivyd -138.90% -53.48% -41.56% CureVac 199.92% -23.03% -19.09%

Which has higher earnings & valuation, XNCR or IVVD?

Invivyd has lower revenue, but higher earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Xencor $125.58M 8.86 -$91.92M -$2.29 N/A Invivyd $53.43M 4.93 -$52.49M -$0.31 N/A

Is XNCR or IVVD more profitable?

Invivyd has a net margin of -138.90% compared to Xencor's net margin of -177.10%. Xencor's return on equity of -28.77% beat Invivyd's return on equity. Company Net Margins Return on Equity Return on Assets Xencor -177.10% -28.77% -20.52% Invivyd -138.90% -53.48% -41.56%

Does the media favor XNCR or IVVD?

In the previous week, Invivyd had 1 more articles in the media than Xencor. MarketBeat recorded 2 mentions for Invivyd and 1 mentions for Xencor. Xencor's average media sentiment score of 0.75 beat Invivyd's score of 0.00 indicating that Xencor is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Invivyd 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Invivyd (IVVD) Competitors

$0.89 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$0.88 -0.01 (-0.98%)

As of 07/2/2026 07:47 PM Eastern

Compare

IVVD vs. SVRA, COLL, MGTX, CVAC, and XNCR

Should you buy Invivyd stock or one of its competitors? MarketBeat compares Invivyd with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Invivyd include Savara (SVRA), Collegium Pharmaceutical (COLL), MeiraGTx (MGTX), CureVac (CVAC), and Xencor (XNCR). These companies are all part of the "pharmaceutical products" industry.

How does Invivyd compare to Savara?

Savara (NASDAQ:SVRA) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

87.9% of Savara shares are owned by institutional investors. Comparatively, 70.4% of Invivyd shares are owned by institutional investors. 5.3% of Savara shares are owned by insiders. Comparatively, 12.3% of Invivyd shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Savara has a net margin of 0.00% compared to Invivyd's net margin of -138.90%. Invivyd's return on equity of -53.48% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-87.19%	-66.42%
Invivyd	-138.90%	-53.48%	-41.56%

Invivyd has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.56	N/A
Invivyd	$53.43M	4.93	-$52.49M	-$0.31	N/A

In the previous week, Invivyd had 2 more articles in the media than Savara. MarketBeat recorded 2 mentions for Invivyd and 0 mentions for Savara. Invivyd's average media sentiment score of 0.00 beat Savara's score of -1.00 indicating that Invivyd is being referred to more favorably in the news media.

Company	Overall Sentiment
Savara	Negative
Invivyd	Neutral

Savara has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market. Comparatively, Invivyd has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market.

Savara presently has a consensus price target of $10.14, indicating a potential upside of 63.07%. Invivyd has a consensus price target of $8.00, indicating a potential upside of 795.05%. Given Invivyd's higher probable upside, analysts plainly believe Invivyd is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Invivyd beats Savara on 11 of the 16 factors compared between the two stocks.

How does Invivyd compare to Collegium Pharmaceutical?

Collegium Pharmaceutical (NASDAQ:COLL) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

Collegium Pharmaceutical has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market. Comparatively, Invivyd has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market.

Collegium Pharmaceutical has a net margin of 9.41% compared to Invivyd's net margin of -138.90%. Collegium Pharmaceutical's return on equity of 95.18% beat Invivyd's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	9.41%	95.18%	16.39%
Invivyd	-138.90%	-53.48%	-41.56%

Collegium Pharmaceutical has higher revenue and earnings than Invivyd. Invivyd is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57M	1.54	$62.87M	$2.04	18.15
Invivyd	$53.43M	4.93	-$52.49M	-$0.31	N/A

In the previous week, Invivyd had 1 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 2 mentions for Invivyd and 1 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 1.00 beat Invivyd's score of 0.00 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.

Company	Overall Sentiment
Collegium Pharmaceutical	Positive
Invivyd	Neutral

Collegium Pharmaceutical presently has a consensus target price of $57.50, indicating a potential upside of 55.28%. Invivyd has a consensus target price of $8.00, indicating a potential upside of 795.05%. Given Invivyd's higher probable upside, analysts plainly believe Invivyd is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.17
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

70.4% of Invivyd shares are held by institutional investors. 1.9% of Collegium Pharmaceutical shares are held by company insiders. Comparatively, 12.3% of Invivyd shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Collegium Pharmaceutical beats Invivyd on 11 of the 16 factors compared between the two stocks.

How does Invivyd compare to MeiraGTx?

Invivyd (NASDAQ:IVVD) and MeiraGTx (NASDAQ:MGTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.

70.4% of Invivyd shares are owned by institutional investors. Comparatively, 67.5% of MeiraGTx shares are owned by institutional investors. 12.3% of Invivyd shares are owned by company insiders. Comparatively, 7.4% of MeiraGTx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Invivyd had 1 more articles in the media than MeiraGTx. MarketBeat recorded 2 mentions for Invivyd and 1 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.42 beat Invivyd's score of 0.00 indicating that MeiraGTx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Invivyd	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MeiraGTx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Invivyd has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

Invivyd has higher earnings, but lower revenue than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invivyd	$53.43M	4.93	-$52.49M	-$0.31	N/A
MeiraGTx	$81.39M	15.84	-$114.20M	-$1.48	N/A

Invivyd presently has a consensus price target of $8.00, suggesting a potential upside of 795.05%. MeiraGTx has a consensus price target of $25.83, suggesting a potential upside of 85.58%. Given Invivyd's higher possible upside, equities analysts plainly believe Invivyd is more favorable than MeiraGTx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Invivyd has a net margin of -138.90% compared to MeiraGTx's net margin of -151.12%. MeiraGTx's return on equity of 0.00% beat Invivyd's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invivyd	-138.90%	-53.48%	-41.56%
MeiraGTx	-151.12%	N/A	-54.96%

Summary

Invivyd beats MeiraGTx on 9 of the 17 factors compared between the two stocks.

How does Invivyd compare to CureVac?

Invivyd (NASDAQ:IVVD) and CureVac (NASDAQ:CVAC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

CureVac has higher revenue and earnings than Invivyd. Invivyd is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invivyd	$53.43M	4.93	-$52.49M	-$0.31	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

Invivyd has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market. Comparatively, CureVac has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market.

CureVac has a net margin of 199.92% compared to Invivyd's net margin of -138.90%. CureVac's return on equity of -23.03% beat Invivyd's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invivyd	-138.90%	-53.48%	-41.56%
CureVac	199.92%	-23.03%	-19.09%

In the previous week, Invivyd had 2 more articles in the media than CureVac. MarketBeat recorded 2 mentions for Invivyd and 0 mentions for CureVac. Invivyd's average media sentiment score of 0.00 equaled CureVac'saverage media sentiment score.

Company	Overall Sentiment
Invivyd	Neutral
CureVac	Neutral

70.4% of Invivyd shares are held by institutional investors. Comparatively, 17.3% of CureVac shares are held by institutional investors. 12.3% of Invivyd shares are held by insiders. Comparatively, 2.2% of CureVac shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Invivyd presently has a consensus target price of $8.00, suggesting a potential upside of 795.05%. Given Invivyd's stronger consensus rating and higher probable upside, research analysts clearly believe Invivyd is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

CureVac beats Invivyd on 9 of the 15 factors compared between the two stocks.

How does Invivyd compare to Xencor?

Xencor (NASDAQ:XNCR) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

Invivyd has lower revenue, but higher earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$125.58M	8.86	-$91.92M	-$2.29	N/A
Invivyd	$53.43M	4.93	-$52.49M	-$0.31	N/A

70.4% of Invivyd shares are owned by institutional investors. 5.1% of Xencor shares are owned by insiders. Comparatively, 12.3% of Invivyd shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Xencor has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, Invivyd has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market.

Xencor presently has a consensus price target of $24.50, suggesting a potential upside of 63.33%. Invivyd has a consensus price target of $8.00, suggesting a potential upside of 795.05%. Given Invivyd's higher possible upside, analysts clearly believe Invivyd is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Invivyd has a net margin of -138.90% compared to Xencor's net margin of -177.10%. Xencor's return on equity of -28.77% beat Invivyd's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-177.10%	-28.77%	-20.52%
Invivyd	-138.90%	-53.48%	-41.56%

In the previous week, Invivyd had 1 more articles in the media than Xencor. MarketBeat recorded 2 mentions for Invivyd and 1 mentions for Xencor. Xencor's average media sentiment score of 0.75 beat Invivyd's score of 0.00 indicating that Xencor is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Invivyd	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Xencor and Invivyd tied by winning 8 of the 16 factors compared between the two stocks.

Get Invivyd News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IVVD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IVVD vs. The Competition

Export

Metric	Invivyd	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$263.32M	$3.76B	$7.16B	$12.47B
Dividend Yield	N/A	2.16%	2.67%	6.50%
P/E Ratio	-2.88	21.80	27.81	24.70
Price / Sales	4.93	324.83	580.48	116.36
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	0.86	8.66	10.96	6.46
Net Income	-$52.49M	$23.81M	$3.57B	$337.01M
7 Day Performance	0.31%	3.39%	2.12%	1.69%
1 Month Performance	-19.48%	6.15%	2.80%	0.67%
1 Year Performance	18.70%	62.61%	33.40%	23.93%

Invivyd Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IVVD Invivyd	2.3223 of 5 stars	$0.89 flat	$8.00 +795.1%	+18.7%	$263.32M	$53.43M	N/A	100	Gap Down
SVRA Savara	1.8565 of 5 stars	$5.69 +3.5%	$10.14 +78.3%	+191.3%	$1.13B	N/A	N/A	20
COLL Collegium Pharmaceutical	3.3254 of 5 stars	$33.45 -0.3%	$57.50 +71.9%	+21.9%	$1.08B	$796.33M	16.40	210
MGTX MeiraGTx	2.7814 of 5 stars	$11.48 +1.4%	$25.83 +125.0%	+85.5%	$1.06B	$79.76M	N/A	300	Positive News Gap Down
CVAC CureVac	N/A	$4.66 flat	$5.50 +18.0%	N/A	$1.05B	$70.74M	6.47	880

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IVVD) was last updated on 7/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Invivyd (IVVD) Competitors